Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Neurogastroenterol Motil ; : e14755, 2024 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-38303121

RESUMO

BACKGROUND: The herbal preparation, STW5-II, improves upper gastrointestinal symptoms, including abdominal fullness, early satiation, and epigastric pain, in patients with functional dyspepsia, and in preclinical models decreases fundic tone and increases antral contractility. The effects of STW5-II on esophago-gastric junction pressure, proximal gastric tone and antropyloroduodenal pressures, disturbances of which may contribute to symptoms associated with disorders of gut-brain interaction, including functional dyspepsia, in humans, have, hitherto, not been evaluated. METHODS: STW5-II or placebo (matched for color, aroma, and alcohol content) were each administered orally, at the recommended dose (20 drops), to healthy male and female volunteers (age: 27 ± 1 years) in a double-blind, randomized fashion, on two separate occasions, separated by 3-7 days, to evaluate effects on (i) esophago-gastric junction pressures following a standardized meal using solid-state high-resolution manometry (part 1, n = 16), (ii) proximal gastric volume using a barostat (part 2, n = 16), and (iii) antropyloroduodenal pressures assessed by high-resolution manometry (part 3, n = 18), for 120 min (part 1) or 180 min (parts 2, 3). KEY RESULTS: STW5-II increased maximum intrabag volume (ml; STW5-II: 340 ± 38, placebo: 251 ± 30; p = 0.007) and intrabag volume between t = 120 and 180 min (p = 0.011), and the motility index of antral pressure waves between t = 60 and 120 min (p = 0.032), but had no effect on esophago-gastric junction, pyloric, or duodenal pressures. CONCLUSIONS & INFERENCES: STW5-II has marked region-specific effects on gastric motility in humans, which may contribute to its therapeutic efficacy in functional dyspepsia.

2.
World J Diabetes ; 14(12): 1717-1720, 2023 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-38222784

RESUMO

Uncontrolled hyperglycemia or poorly managed disease increases the propensity for a number of diabetes-related complications targeting major organs including the heart, eyes, and kidney. Although the mechanisms by which diabetes induces cardiovascular diseases include oxidative stress and inflammation, when insulin resistance remains the key to the pathogenesis, as implicated in the two reviews in this issue. This editorial mainly comments on the potential preventive application of glycyrrhetinic acid (or 18ß-GA) in relation to diabetic nephropathy. The thera-peutic or preventive effects of 18ß-GA, as a hydrolytic product of glycyrrhizic acid that is a component of licorice, have been appreciated in other disorders, but have received much less attention in relation to diabetic complications. A study in this issue has identified 18ß-GA as a therapeutic for preventing diabetic nephropathy and provides evidence to support efficacy in cultured human renal tubule cells in vitro. Although it represents a pilot study, the observations support a new therapeutic approach that warrants further ex-ploration.

3.
Nutrients ; 13(8)2021 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-34444986

RESUMO

Postprandial hypotension (PPH) is an important and under-recognised disorder resulting from inadequate compensatory cardiovascular responses to meal-induced splanchnic blood pooling. Current approaches to management are suboptimal. Recent studies have established that the cardiovascular response to a meal is modulated profoundly by gastrointestinal factors, including the type and caloric content of ingested meals, rate of gastric emptying, and small intestinal transit and absorption of nutrients. The small intestine represents the major site of nutrient-gut interactions and associated neurohormonal responses, including secretion of glucagon-like peptide-1, glucose-dependent insulinotropic peptide and somatostatin, which exert pleotropic actions relevant to the postprandial haemodynamic profile. This review summarises knowledge relating to the role of these gut peptides in the cardiovascular response to a meal and their potential application to the management of PPH.


Assuntos
Pressão Sanguínea , Polipeptídeo Inibidor Gástrico/sangue , Fármacos Gastrointestinais/farmacologia , Peptídeo 1 Semelhante ao Glucagon/sangue , Hipotensão , Período Pós-Prandial , Somatostatina/sangue , Acarbose/farmacologia , Acarbose/uso terapêutico , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Fármacos Gastrointestinais/uso terapêutico , Glucagon/sangue , Receptor do Peptídeo Semelhante ao Glucagon 1/sangue , Humanos , Hipotensão/tratamento farmacológico , Hipotensão/fisiopatologia , Insulina/sangue , Peptídeos , Circulação Esplâncnica
4.
Diabetes Res Clin Pract ; 171: 108618, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33310174

RESUMO

AIMS: In healthy individuals, intragastric administration of the branched-chain amino acids, leucine and isoleucine, diminishes the glycaemic response to a mixed-nutrient drink, apparently by stimulating insulin and slowing gastric emptying, respectively. This study aimed to evaluate the effects of leucine and isoleucine on postprandial glycaemia and gastric emptying in type-2 diabetes mellitus (T2D). METHODS: 14 males with T2D received, on 3 separate occasions, in double-blind, randomised fashion, either 10 g leucine, 10 g isoleucine or control, intragastrically 30 min before a mixed-nutrient drink (500 kcal; 74 g carbohydrates, 18 g protein, 15 g fat). Plasma glucose, insulin and glucagon were measured from 30 min pre- until 120 min post-drink. Gastric emptying of the drink was also measured. RESULTS: Leucine and isoleucine stimulated insulin, both before and after the drink (all P < 0.05; peak (mU/L): control: 70 ± 15; leucine: 88 ± 17; isoleucine: 74 ± 15). Isoleucine stimulated (P < 0.05), and leucine tended to stimulate (P = 0.078), glucagon before the drink, and isoleucine stimulated glucagon post-drink (P = 0.031; peak (pg/mL): control: 62 ± 5; leucine: 70 ± 9; isoleucine: 69 ± 6). Neither amino acid affected gastric emptying or plasma glucose (peak (mmol/L): control: 12.0 ± 0.5; leucine: 12.5 ± 0.7; isoleucine: 12.0 ± 0.6). CONCLUSIONS: In contrast to health, in T2D, leucine and isoleucine, administered intragastrically in a dose of 10 g, do not lower the glycaemic response to a mixed-nutrient drink. This finding argues against a role for 'preloads' of either leucine or isoleucine in the management of T2D.


Assuntos
Aminoácidos de Cadeia Ramificada/uso terapêutico , Glicemia/efeitos dos fármacos , Diabetes Mellitus Tipo 2/sangue , Esvaziamento Gástrico/efeitos dos fármacos , Isoleucina/uso terapêutico , Leucina/uso terapêutico , Período Pós-Prandial/efeitos dos fármacos , Adulto , Idoso , Aminoácidos de Cadeia Ramificada/farmacologia , Estudos Cross-Over , Suplementos Nutricionais , Método Duplo-Cego , Bebidas Energéticas , Humanos , Isoleucina/farmacologia , Leucina/farmacologia , Masculino , Pessoa de Meia-Idade
5.
Nutrients ; 12(11)2020 Oct 29.
Artigo em Inglês | MEDLINE | ID: mdl-33138061

RESUMO

Ageing is associated with changes in feeding behavior. We have reported that there is suppression of energy intake three hours after whey protein drink ingestion in young, but not older, men. This study aimed to determine these effects over a time period of 9 h. Fifteen younger (27 ± 1 years, 25.8 ± 0.7 kg/m2) and 15 older (75 ± 2 years, 26.6 ± 0.8 kg/m2) healthy men were studied on three occasions on which they received, in a randomized order, a 30 g/120 kcal, 70 g/280 kcal whey-protein, or control (~2 kcal) drink. Ad-libitum energy intake (sum of breakfast, lunch, and dinner) was suppressed in a protein load responsive fashion (P = 0.001). Suppression was minimal at breakfast, substantial at lunch (~-16%, P = 0.001), no longer present by dinner, and was less in older than younger men (-3 ± 4% vs. -8 ± 4%, P = 0.027). Cumulative protein intake was increased in the younger and older men (+20% and +42%, P < 0.001). Visual analogue scale ratings of fullness were higher and desire to eat and prospective food consumption were lower after protein vs. control, and these effects were smaller in older vs. younger men (interaction effect P < 0.05). These findings support the use of whey-protein drink supplements in older people who aim to increase their protein intake without decreasing their overall energy intake.


Assuntos
Fatores Etários , Apetite/efeitos dos fármacos , Ingestão de Energia/efeitos dos fármacos , Refeições/efeitos dos fármacos , Proteínas do Soro do Leite/administração & dosagem , Adulto , Idoso , Depressores do Apetite/administração & dosagem , Bebidas , Desjejum/efeitos dos fármacos , Suplementos Nutricionais , Voluntários Saudáveis , Humanos , Almoço/efeitos dos fármacos , Masculino , Fatores de Tempo
6.
Nutrients ; 10(6)2018 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-29880750

RESUMO

Glutamine is a potent stimulus for the release of glucagon-like peptide-1, which increases postprandial insulin and slows gastric emptying (GE). We determined the effects of glutamine on GE of, and glycaemic responses to, low- and high-nutrient drinks in eight healthy males (mean age 21.6 ± 0.7 years and BMI 22.9 ± 0.7 kg/m²). Participants were studied on four occasions on which they consumed either a low-nutrient (beef soup; 18 kcal) or high-nutrient (75 g dextrose; 255 kcal) drink, each with or without 30 g of glutamine (120 kcal), in a randomised, crossover design. GE (2D ultrasound), blood glucose and plasma insulin concentrations were measured concurrently. Glutamine slowed GE (half emptying time (T50)) of both low- (45 ± 3 min vs. 26 ± 2 min, p < 0.001), and high-nutrient, (100 ± 5 min vs. 77 ± 5 min, p = 0.03) drinks, however, there was no effect on GE of the high nutrient drinks when expressed as kcal/min (3.39 ± 0.21 kcal/min vs. 3.81 ± 0.20 kcal/min, p = 0.25). There was no change in blood glucose after the low-nutrient drinks with or without glutamine, despite a slight increase in plasma insulin with glutamine (p = 0.007). The rise in blood glucose following the high-nutrient drink (p = 0.0001) was attenuated during the first 60 min by glutamine (p = 0.007). We conclude that in healthy subjects, glutamine slows GE of both low- and high-nutrient drinks comparably and attenuates the rise in blood glucose after the high-nutrient glucose drink.


Assuntos
Glicemia/efeitos dos fármacos , Suplementos Nutricionais , Bebidas Energéticas , Esvaziamento Gástrico/efeitos dos fármacos , Glutamina/administração & dosagem , Valor Nutritivo , Administração Oral , Fatores Etários , Biomarcadores/sangue , Glicemia/metabolismo , Estudos Cross-Over , Método Duplo-Cego , Voluntários Saudáveis , Humanos , Insulina/sangue , Masculino , Austrália do Sul , Fatores de Tempo , Adulto Jovem
7.
Nutrients ; 10(1)2018 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-29329233

RESUMO

Protein-rich supplements are used widely for the prevention and management of malnutrition in older people. We have reported that healthy older, compared to younger, adults have less suppression of energy intake by whey-protein-effects on appetite-related hormones are unknown. The objective was to determine the effects of intraduodenally administered whey-protein on glucose, gut hormone, and amino acid concentrations, and their relation to subsequent ad libitum energy intake at a buffet meal, in healthy older and younger men. Hydrolyzed whey-protein (30 kcal, 90 kcal, and 180 kcal) and a saline control (~0 kcal) were infused intraduodenally for 60 min in 10 younger (19-29 years, 73 ± 2 kg, 22 ± 1 kg/m²) and 10 older (68-81 years, 79 ± 2 kg, 26 ± 1 kg/m²) healthy men in a randomized, double-blind fashion. Plasma insulin, glucagon, gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), peptide tyrosine-tyrosine (PYY), and amino acid concentrations, but not blood glucose, increased, while ghrelin decreased during the whey-protein infusions. Plasma GIP concentrations were greater in older than younger men. Energy intake correlated positively with plasma ghrelin and negatively with insulin, glucagon, GIP, GLP-1, PYY, and amino acids concentrations (p < 0.05). In conclusion, intraduodenal whey-protein infusions resulted in increased GIP and comparable ghrelin, insulin, glucagon, GIP, GLP-1, PYY, and amino acid responses in healthy older and younger men, which correlated to subsequent energy intake.


Assuntos
Aminoácidos/sangue , Glicemia/metabolismo , Hormônios Gastrointestinais/sangue , Proteínas do Soro do Leite/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Apetite , Método Duplo-Cego , Glucagon/sangue , Humanos , Insulina/sangue , Masculino , Adulto Jovem
8.
Nutrients ; 10(1)2017 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-29267221

RESUMO

Protein-rich supplements are used widely to prevent and manage undernutrition in older people. We have previously shown that healthy older, compared to younger, adults have less suppression of energy intake by whey protein-although the effects of age on appetite-related gut hormones are largely unknown. The aim of this study was to determine and compare the acute effects of whey protein loads on blood glucose and plasma gut hormone concentrations in older and younger adults. Sixteen healthy older (eight men, eight women; mean ± SEM: age: 72 ± 1 years; body mass index: 25 ± 1 kg/m²) and 16 younger (eight men, eight women; 24 ± 1 years; 23 ± 0.4 kg/m²) adults were studied on three occasions in which they ingested 30 g (120 kcal) or 70 g (280 kcal) whey protein, or a flavored-water control drink (~2 kcal). At regular intervals over 180 min, blood glucose and plasma insulin, glucagon, ghrelin, cholecystokinin (CCK), gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) concentrations were measured. Plasma ghrelin was dose-dependently suppressed and insulin, glucagon, CCK, GIP, and GLP-1 concentrations were dose-dependently increased by the whey protein ingestion, while blood glucose concentrations were comparable during all study days. The stimulation of plasma CCK and GIP concentrations was greater in older than younger adults. In conclusion, orally ingested whey protein resulted in load-dependent gut hormone responses, which were greater for plasma CCK and GIP in older compared to younger adults.


Assuntos
Envelhecimento/sangue , Glicemia/metabolismo , Colecistocinina/sangue , Suplementos Nutricionais , Polipeptídeo Inibidor Gástrico/sangue , Grelina/sangue , Peptídeo 1 Semelhante ao Glucagon/sangue , Glucagon/sangue , Insulina/sangue , Proteínas do Soro do Leite/administração & dosagem , Administração Oral , Adulto , Fatores Etários , Idoso , Bebidas , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Austrália do Sul , Fatores de Tempo , Adulto Jovem
9.
Am J Clin Nutr ; 106(3): 865-877, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28747330

RESUMO

Background: Protein- and energy-rich supplements are used widely for the management of malnutrition in the elderly. Information about the effects of protein on energy intake and related gastrointestinal mechanisms and whether these differ between men and women is limited.Objective: We determined the effects of whey protein on energy intake, appetite, gastric emptying, and gut hormones in healthy older men and women.Design: Eight older women and 8 older men [mean ± SEM age: 72 ± 1 y; body mass index (in kg/m2): 25 ± 1] were studied on 3 occasions in which they received protein loads of 30 g (120 kcal) or 70 g (280 kcal) or a flavored water control drink (0 kcal). At regular intervals over 180 min, appetite (visual analog scales), gastric emptying (3-dimensional ultrasonography), and blood glucose and plasma gut-hormone concentrations [insulin, glucagon, ghrelin, cholecystokinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine tyrosine (PYY)] were measured, and ad libitum energy intake was quantified from a buffet meal (180-210 min; energy intake, appetite, and gastric emptying in the men have been published previously).Results: Energy intake at the buffet meal was ∼80% higher in older men than in older women (P < 0.001). Energy intake was not suppressed by protein compared with the control in men or women (P > 0.05). There was no effect of sex on gastric emptying, appetite, gastrointestinal symptoms, glucose, or gut hormones (P > 0.05). There was a protein load-dependent slowing of gastric emptying, an increase in concentrations of insulin, glucagon, cholecystokinin, GIP, GLP-1, and PYY, and an increase in total energy intake (drink plus meal: 12% increase with 30 g and 32% increase with 70 g; P < 0.001). Energy intake at the buffet meal was inversely related to the stomach volume and area under the curve of hormone concentrations (P < 0.05).Conclusion: In older men and women, whey-protein drinks load-dependently slow gastric emptying and alter gut hormone secretion compared with a control but have no suppressive effect on subsequent ad libitum energy intake. This trial was registered at www.anzctr.org.au as ACTRN12612000941864.


Assuntos
Apetite/efeitos dos fármacos , Ingestão de Energia/efeitos dos fármacos , Esvaziamento Gástrico/efeitos dos fármacos , Hormônios Gastrointestinais/sangue , Resposta de Saciedade/efeitos dos fármacos , Estômago/efeitos dos fármacos , Proteínas do Soro do Leite/farmacologia , Idoso , Área Sob a Curva , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Humanos , Masculino , Refeições , Proteínas do Soro do Leite/administração & dosagem
10.
Nutrition ; 32(5): 553-9, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26792024

RESUMO

OBJECTIVE: Hydroxycitric acid (HCA), derived from the fruit Garcinia cambogia, reduces the rate of glucose absorption and lowers postprandial glycemia in rodents, but its effect in humans is unknown. The aim of this study was to investigate the effects of small intestinal perfusion with HCA on glucose absorption, as well as the incretin and glycemic responses to a subsequent intraduodenal glucose infusion, in both healthy individuals and patients with type 2 diabetes. METHODS: Twelve healthy participants and 8 patients with type 2 diabetes received an intraduodenal infusion of HCA (2800 mg in water) or control (water) over 60 min, followed by an intraduodenal infusion of 60 g glucose over 120 min, in a double-blind, randomized crossover design. In healthy individuals, 5 g 3-O-methylglucose (3-OMG) was co-infused with glucose as a marker of glucose absorption. Blood was sampled frequently. RESULTS: In healthy individuals, blood glucose was lower with HCA than control, both before and during the intraduodenal glucose infusion (P < 0.05 for each). Plasma glucose-dependent insulinotropic polypeptide (GIP; P = 0.01) and glucagon (P = 0.06) were higher with HCA, but there were no differences in plasma glucagon-like peptide (GLP)-1, insulin, or serum 3-OMG concentrations. In patients with type 2 diabetes, blood glucose, and plasma GIP, GLP-1, and insulin did not differ between HCA and control either before or after intraduodenal glucose, but during glucose infusion, plasma glucagon was higher with HCA (P = 0.04). CONCLUSION: In healthy individuals, small intestinal exposure to HCA resulted in a modest reduction in glycemia and stimulation of plasma GIP and glucagon, but no effect on plasma GLP-1 or insulin, or on glucose absorption. HCA had no effect on glycemia in patients with type 2 diabetes.


Assuntos
Citratos/uso terapêutico , Diabetes Mellitus Tipo 2/dietoterapia , Carboidratos da Dieta/metabolismo , Glucose/metabolismo , Hipoglicemiantes/uso terapêutico , Incretinas/metabolismo , Absorção Intestinal , 3-O-Metilglucose/sangue , 3-O-Metilglucose/metabolismo , Adulto , Idoso , Biomarcadores/sangue , Biomarcadores/metabolismo , Citratos/administração & dosagem , Citratos/efeitos adversos , Estudos Cross-Over , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/metabolismo , Carboidratos da Dieta/administração & dosagem , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Duodeno/metabolismo , Feminino , Glucose/administração & dosagem , Humanos , Hiperglicemia/prevenção & controle , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Incretinas/sangue , Mucosa Intestinal/metabolismo , Intubação Gastrointestinal , Masculino , Pessoa de Meia-Idade
11.
Am J Clin Nutr ; 100(4): 1108-15, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25099545

RESUMO

BACKGROUND: Protein-rich supplements are used widely for the prevention and management of undernutrition in older people. The use of protein supplements in older people could, however, be counterproductive by reducing appetite and overall energy intake. OBJECTIVE: The objective was to determine whether aging influences the effects of protein loads, administered directly into the small intestine, on energy intake, antropyloroduodenal motility, and appetite. DESIGN: Intraduodenal infusions (240 mL, 60 min) of saline (0 kcal, control) and protein (hydrolyzed whey) loads of 30, 90, and 180 kcal were followed by an ad libitum buffet meal in 10 young (19-29 y) and 10 healthy older (68-81 y) men. Suppression of energy intake (kcal) at the meal by protein infusion compared with control was calculated. RESULTS: In young subjects, a dose-responsive suppression (±SEM) of energy intake was found at the buffet meal by protein (suppression at 30 kcal: 7 ± 8%, P = 0.189; 90 kcal: 17 ± 8%, P = 0.054; 180 kcal: 33 ± 7%, P = 0.002), whereas suppression was observed only after the 180-kcal load in older subjects (30 kcal: 7 ± 4% increase, P = 0.126; 90 kcal: 6 ± 7% increase, P = 0.291; 180 kcal: 17 ± 6% suppression, P = 0.016). Suppression of energy intake by protein was less in older than in young subjects (P < 0.005). In young subjects, total energy intake (meal + infusion) on the 180-kcal protein-infusion day was lower than that on the control day (P = 0.041), whereas in older subjects it was greater on the 30-kcal (P = 0.033) and 90-kcal (P = 0.016) infusion days. Energy intake was inversely related to isolated pyloric pressure waves (r = -0.32, P = 0.013) and positively related to antral (r = 0.30, P = 0.021) and duodenal (r = 0.35, P = 0.006) pressure waves. Suppression of energy intake by protein was inversely related to the change in isolated pyloric pressure waves (r = -0.35, P = 0.027) and positively related to duodenal pressure waves (r = 0.32, P = 0.044). CONCLUSIONS: Intraduodenal protein suppresses appetite and energy intake less in healthy older than in young adults. In older subjects, intraduodenal protein at low doses increased overall energy intake, which supports the use of protein supplements in undernourished older people. This trial was registered at www.anzctr.org.au as 12612000906853.


Assuntos
Envelhecimento/fisiologia , Apetite/efeitos dos fármacos , Proteínas Alimentares/administração & dosagem , Suplementos Nutricionais , Ingestão de Energia/efeitos dos fármacos , Motilidade Gastrointestinal/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Peso Corporal , Estudos Cross-Over , Voluntários Saudáveis , Humanos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/metabolismo , Masculino , Desnutrição/tratamento farmacológico , Refeições , Inquéritos e Questionários , Adulto Jovem
12.
Expert Rev Gastroenterol Hepatol ; 7(2): 127-39, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23363262

RESUMO

Delayed gastric emptying affects a substantial proportion of patients with long-standing diabetes, and when associated with symptoms and/or disordered glycemic control, affects quality of life adversely. Important clinicopathological insights have recently been gained by the systematic analysis of gastric biopsies from patients with severe diabetic gastroparesis, which may stimulate the development of new therapies in the coming decade. Experience with prokinetic therapies and treatments, such as pyloric botulinum toxin injection and gastric electrical stimulation, has established that relief of symptoms does not correlate closely with acceleration of delayed gastric emptying, and that well-designed controlled trials are essential to determine the efficacy of emerging therapies.


Assuntos
Complicações do Diabetes/fisiopatologia , Complicações do Diabetes/terapia , Gastroparesia/fisiopatologia , Gastroparesia/terapia , Antieméticos/uso terapêutico , Toxinas Botulínicas/administração & dosagem , Terapias Complementares , Complicações do Diabetes/diagnóstico , Complicações do Diabetes/epidemiologia , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/fisiopatologia , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/fisiopatologia , Terapia por Estimulação Elétrica , Esvaziamento Gástrico , Motilidade Gastrointestinal/fisiologia , Gastroparesia/diagnóstico , Gastroparesia/epidemiologia , Humanos , Imageamento por Ressonância Magnética , Contração Muscular , Células-Tronco Neurais/transplante , Fármacos Neuromusculares/administração & dosagem , Estado Nutricional , Manejo da Dor , Prognóstico
13.
Am J Clin Nutr ; 95(6): 1396-402, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22572649

RESUMO

BACKGROUND: The gastrokinetic drug erythromycin is commonly administered to critically ill patients during intragastric feeding to augment small intestinal nutrient delivery. However, erythromycin has been reported to increase the prevalence of diarrhea, which may reflect reduced absorption and/or accelerated small intestinal transit. OBJECTIVE: The objective was to evaluate the effects of intravenous erythromycin on small intestinal nutrient absorption and transit in the critically ill. DESIGN: On consecutive days, erythromycin (200 mg in 20 mL 0.9% saline) or placebo (20 mL 0.9% saline) were infused intravenously between -20 and 0 min in a randomized, blinded, crossover fashion. Between 0 and 30 min, a liquid nutrient containing 3-O-methylglucose (3-OMG), [13C]triolein, and [(99m)Tc]sulfur colloid was administered directly into the small intestine at 2 kcal/min. Serum 3-OMG concentrations and exhaled (13)CO2 (indices of glucose and lipid absorption, respectively) were measured. Cecal arrival of the infused nutrient was determined by scintigraphy. Data are medians (ranges) and were analyzed by using Wilcoxon's signed-rank test. RESULTS: Thirty-two mechanically ventilated patients were studied. Erythromycin increased small intestinal glucose absorption [3-OMG AUC360: 105.2 (28.9-157.0) for erythromycin compared with 91.8 (51.4-147.9) mmol/L · min for placebo; P = 0.029] but tended to reduce lipid absorption [cumulative percentage dose (13)CO2 recovered: 10.4 (0-90.6) compared with 22.6 (0-100) %; P = 0.06]. A trend to slower transit was observed after erythromycin [300 (39-360) compared with 228 (33-360) min; P = 0.07]. CONCLUSIONS: Acute administration of erythromycin increases small intestinal glucose absorption in the critically ill, but there was a tendency for the drug to reduce small intestinal lipid absorption and slow transit. These observations have implications for the use of erythromycin as a gastrokinetic drug in the critically ill. This trial was registered in the Australian New Zealand Clinical Trials Registry as ACTRN 12610000615088.


Assuntos
Estado Terminal/terapia , Eritromicina/uso terapêutico , Trânsito Gastrointestinal/efeitos dos fármacos , Glucose/metabolismo , Intestino Delgado/efeitos dos fármacos , Metabolismo dos Lipídeos/efeitos dos fármacos , Distúrbios Nutricionais/prevenção & controle , Adulto , Idoso , Metabolismo dos Carboidratos/efeitos dos fármacos , Dióxido de Carbono/metabolismo , Ceco/metabolismo , Estudos Cross-Over , Diarreia/induzido quimicamente , Método Duplo-Cego , Nutrição Enteral/métodos , Eritromicina/efeitos adversos , Eritromicina/farmacologia , Feminino , Fármacos Gastrointestinais/efeitos adversos , Fármacos Gastrointestinais/farmacologia , Fármacos Gastrointestinais/uso terapêutico , Humanos , Infusões Intravenosas , Absorção Intestinal/efeitos dos fármacos , Intestino Delgado/metabolismo , Masculino , Pessoa de Meia-Idade , Distúrbios Nutricionais/metabolismo , Respiração Artificial , Enxofre/metabolismo , Adulto Jovem
14.
Stroke ; 43(5): 1408-11, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22382156

RESUMO

BACKGROUND AND PURPOSE: We evaluated recanalization rates, clinical outcomes, and safety when manual aspiration thrombectomy is used in conjunction with other thrombolytic modalities in a consecutive case series of patients with large vessel intracranial occlusion. METHODS: We conducted a retrospective review of a prospectively acquired acute endovascular stroke database. Manual aspiration thrombectomy was carried out with Distal Access and Penumbra reperfusion catheters of different sizes placed in the thrombus and aspirated with a syringe. RESULTS: We identified 191 patients: Occlusion locations were as follows: M1% to 50%, M2% to 10%, internal carotid artery terminus 25%, and vertebrobasilar 15%. Median treatment duration was 90 minutes. Recanalization results were Thrombolysis in Myocardial Ischemia 2/3 93%, Thrombolysis in Myocardial Ischemia 3 27%, Thrombolysis In Cerebral Infarction 2a/2b/3 91%, Thrombolysis In Cerebral Infarction 2b/3 71%, and Thrombolysis In Cerebral Infarction 3 25%. Larger catheters were associated with higher recanalization rates. Parenchymal hematoma rate was 13.6%. The favorable outcome (90-day modified Rankin Scale ≤ 2) rate was 54%. Mortality at 90 days was 25%. CONCLUSIONS: Manual aspiration thrombectomy is a useful addition to the armamentarium of endovascular treatment modalities for acute stroke.


Assuntos
Procedimentos Endovasculares/métodos , Manipulações Musculoesqueléticas/métodos , Acidente Vascular Cerebral/cirurgia , Trombectomia/métodos , Idoso , Algoritmos , Transtornos Cerebrovasculares/complicações , Transtornos Cerebrovasculares/cirurgia , Procedimentos Endovasculares/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Manipulações Musculoesqueléticas/efeitos adversos , Estudos Prospectivos , Estudos Retrospectivos , Acidente Vascular Cerebral/etiologia , Sucção/efeitos adversos , Sucção/métodos , Trombectomia/efeitos adversos , Resultado do Tratamento
15.
Br J Nutr ; 106(4): 583-7, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21554816

RESUMO

In healthy older subjects, the glycaemic response to carbohydrate-containing meals is dependent on gastric emptying and intestinal absorption; when the latter is slowed, the magnitude of the rise in glucose is attenuated. The oligosaccharide α-cyclodextrin has been reported to diminish the glycaemic response to starch in young adults; this effect has been attributed to the inhibition of pancreatic amylase. We examined the effects of α-cyclodextrin on gastric emptying of, and the glycaemic and insulinaemic responses to, oral sucrose in healthy older subjects; as sucrose is hydrolysed by intestinal disaccharides, any effect(s) of α-cyclodextrin would not be attributable to amylase inhibition. A total of ten subjects (seven males and three females, age 68-76 years) were studied on 2 d. Gastric emptying, blood glucose and serum insulin were measured after ingestion of a 300 ml drink containing 100 g sucrose, labelled with (99m)Tc-sulphur colloid, with or without 10 g α-cyclodextrin. Gastric emptying was slowed slightly by α-cyclodextrin; this effect was evident between 135 and 195 min and was associated with a slight increase (P < 0·05) in distal stomach retention. After α-cyclodextrin, blood glucose was slightly less (P < 0·05) at 60 min, and serum insulin was less (P < 0·0005) at 90 and 120 min. There was no difference in the incremental areas under the curve (iAUC) for blood glucose, but there was a trend for the iAUC for serum insulin to be lower (P = 0·09) after α-cyclodextrin. We conclude that in a dose of 10 g, α-cyclodextrin has modest effects to slow gastric emptying of, and modify the glycaemic and insulinaemic responses to, oral sucrose, probably due to delayed intestinal carbohydrate absorption.


Assuntos
Sacarose Alimentar/metabolismo , Suplementos Nutricionais , Esvaziamento Gástrico , Hiperglicemia/prevenção & controle , Hipoglicemiantes/metabolismo , alfa-Ciclodextrinas/metabolismo , Idoso , Glicemia/análise , Diarreia/induzido quimicamente , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Insulina/sangue , Absorção Intestinal , Cinética , Masculino , Pacientes Desistentes do Tratamento , Tecnécio , alfa-Ciclodextrinas/administração & dosagem , alfa-Ciclodextrinas/efeitos adversos
16.
Crit Care ; 15(1): R35, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21255422

RESUMO

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient infusion in stress-induced hyperglycaemia and reduces fasting glucose concentrations in critically ill patients with type-2 diabetes. The objective of this study was to evaluate the effects of acute administration of GLP-1 on the glycaemic response to small intestinal nutrient infusion in critically ill patients with pre-existing type-2 diabetes. METHODS: Eleven critically ill mechanically-ventilated patients with known type-2 diabetes received intravenous infusions of GLP-1 (1.2 pmol/kg/minute) and placebo from t = 0 to 270 minutes on separate days in randomised double-blind fashion. Between t = 30 to 270 minutes a liquid nutrient was infused intraduodenally at a rate of 1 kcal/min via a naso-enteric catheter. Blood glucose, serum insulin and C-peptide, and plasma glucagon were measured. Data are mean ± SEM. RESULTS: GLP-1 attenuated the overall glycaemic response to nutrient (blood glucose AUC30-270 min: GLP-1 2,244 ± 184 vs. placebo 2,679 ± 233 mmol/l/minute; P = 0.02). Blood glucose was maintained at < 10 mmol/l in 6/11 patients when receiving GLP-1 and 4/11 with placebo. GLP-1 increased serum insulin at 270 minutes (GLP-1: 23.4 ± 6.7 vs. placebo: 16.4 ± 5.5 mU/l; P < 0.05), but had no effect on the change in plasma glucagon. CONCLUSIONS: Exogenous GLP-1 in a dose of 1.2 pmol/kg/minute attenuates the glycaemic response to small intestinal nutrient in critically ill patients with type-2 diabetes. Given the modest magnitude of the reduction in glycaemia the effects of GLP-1 at higher doses and/or when administered in combination with insulin, warrant evaluation in this group. TRIAL REGISTRATION: ANZCTR:ACTRN12610000185066.


Assuntos
Glicemia/efeitos dos fármacos , Cuidados Críticos/métodos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Nutrição Enteral/métodos , Peptídeo 1 Semelhante ao Glucagon/uso terapêutico , Hipoglicemiantes/uso terapêutico , Estado Terminal , Diabetes Mellitus Tipo 2/terapia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Piloro , Resultado do Tratamento
17.
Appetite ; 55(3): 473-7, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20800632

RESUMO

Human aging is associated with a reduction in appetite and food intake. Increased activity of the satiety hormone, cholecystokinin (CCK), may be partly responsible. This study aimed to determine whether an increase in fat and energy intake modifies the suppressive effects of CCK-8 on appetite and energy intake. Fourteen healthy older adults completed three separate dietary periods, a 14-day and a 7-day normal diet (ND; 8272 ± 480 kJ/day; 35% fat), and a 14-day high-fat diet (HFD; 11,642 ± 414 kJ/day; 43% fat), in randomised order. Immediately following each diet, subjects received, in single-blinded fashion, a 30-min intravenous infusion of either CCK-8 (1.5 ng/kg/min) (ND-CCK, HFD-CCK) or 0.9% saline (ND-SAL), the latter following only ND. Plasma CCK concentrations, appetite responses and energy intake at a buffet meal were determined. Energy intake at the buffet meal was higher on the ND-SAL study day (3349 ± 224 kJ), when compared with either ND-CCK (3023 ± 317 kJ) or HFD-CCK (2905 ± 316 kJ). The suppression of energy intake by CCK-8 infusion did not differ between the two diets. We conclude that suppression of energy intake by exogenous CCK-8 does not appear to be attenuated by incorporation of supplemental high-energy, high-fat drinks in the diet of healthy older adults.


Assuntos
Apetite/efeitos dos fármacos , Colecistocinina/farmacologia , Gorduras na Dieta/farmacologia , Suplementos Nutricionais , Ingestão de Energia/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/fisiologia , Colecistocinina/sangue , Feminino , Humanos , Infusões Intravenosas , Masculino , Método Simples-Cego
18.
Regul Pept ; 159(1-3): 156-9, 2010 Jan 08.
Artigo em Inglês | MEDLINE | ID: mdl-19914303

RESUMO

BACKGROUND AND AIMS: In rodents, cephalosporin antibiotics can mimic peptones and stimulate release of cholecystokinin (CCK), a hormone that slows gastric emptying. The rate of gastric emptying is a major determinant of postprandial blood glucose and insulin concentrations. We therefore evaluated the effect of orally administered cefaclor on plasma CCK and gastric emptying, as well as postprandial glycemic and insulinemic responses, in healthy humans. MATERIALS AND METHODS: We studied 8 healthy subjects on two days in double-blind, randomized order. On each day, subjects consumed 1000 mg cefaclor or placebo 30 min before a mashed potato meal labeled with (13)C octanoic acid. Blood and breath samples were collected for 4h after the meal. RESULTS: Blood glucose, serum insulin and plasma CCK increased in response to the carbohydrate meal on both study days, and cefaclor had no effect on these responses. Similarly, the gastric half-emptying time (measured by breath test) did not differ (placebo: 137.5+/-6.0 min vs. cefaclor: 143.1+/-8.0 min). CONCLUSION: Cefaclor, when given before a meal in the form of a capsule, does not stimulate CCK release or slow gastric emptying in healthy humans.


Assuntos
Antibacterianos/administração & dosagem , Glicemia/metabolismo , Cefaclor/administração & dosagem , Colecistocinina/sangue , Esvaziamento Gástrico/efeitos dos fármacos , Insulina/sangue , Adulto , Caprilatos/farmacologia , Isótopos de Carbono/farmacologia , Método Duplo-Cego , Feminino , Humanos , Masculino , Peptonas/metabolismo , Solanum tuberosum
19.
Calcif Tissue Int ; 85(1): 31-6, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19488668

RESUMO

We challenge the widespread assumption that malabsorption of calcium per se causes secondary hyperparathyroidism. Serum parathyroid hormone (PTH) does not rise at the menopause despite the fall in calcium absorption, nor is it raised in osteoporotic women with vertebral fractures despite their low calcium absorption. The age-related rise in serum PTH can be accounted for by the age-related fall in serum 25(OH)D and/or decline in renal function with consequent loss of the calcemic action of vitamin D on bone. The reference interval for serum PTH is established in the fasting state when it is at the top of its diurnal cycle and is maintaining serum ionized calcium at the expense of bone to meet the calcium being lost through skin, bowel, and kidneys. There is no evidence that the fasting PTH is influenced by the previous day's intake or absorption of calcium, although it can be lowered by a large evening calcium supplement. Malabsorption of calcium-like dietary calcium deficiency-is a risk factor for osteoporosis because it reduces or prevents the normal food-related daytime fall in PTH and bone resorption, not because it causes secondary hyperparathyroidism.


Assuntos
Cálcio/metabolismo , Hiperparatireoidismo Secundário/etiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Reabsorção Óssea/metabolismo , Cálcio/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Pós-Menopausa/metabolismo
20.
Crit Care ; 13(3): R67, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19439067

RESUMO

INTRODUCTION: Hyperglycaemia occurs frequently in the critically ill, affects outcome adversely, and is exacerbated by enteral feeding. Furthermore, treatment with insulin in this group is frequently complicated by hypoglycaemia. In healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (GLP-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying. Because the former effects are glucose-dependent, the use of GLP-1 is not associated with hypoglycaemia. The objective of this study was to establish if exogenous GLP-1 attenuates the glycaemic response to enteral nutrition in patients with critical illness induced hyperglycaemia. METHODS: Seven mechanically ventilated critically ill patients, not previously known to have diabetes, received two intravenous infusions of GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) over 270 minutes. Infusions were administered on consecutive days in a randomised, double-blind fashion. On both days a mixed nutrient liquid was infused, via a post-pyloric feeding catheter, at a rate of 1.5 kcal/min between 30 and 270 minutes. Blood glucose and plasma GLP-1, insulin and glucagon concentrations were measured. RESULTS: In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30-270 min GLP-1 (2077 +/- 144 mmol/l min) vs placebo (2568 +/- 208 mmol/l min); P = 0.02) and the peak blood glucose (GLP-1 (10.1 +/- 0.7 mmol/l) vs placebo (12.7 +/- 1.0 mmol/l); P < 0.01). The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 +/- 2.7) vs. placebo (5.8 +/- 1.8); P = 0.02) but there was no difference in absolute insulin concentrations. There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 +/- 12 pmol/ml) vs. placebo (104 +/- 10 pmol/ml); P < 0.01). CONCLUSIONS: Acute, exogenous GLP-1 infusion markedly attenuates the glycaemic response to enteral nutrition in the critically ill. These observations suggest that GLP-1 and/or its analogues have the potential to manage hyperglycaemia in the critically ill. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry number: ACTRN12609000093280.


Assuntos
Nutrição Enteral/efeitos adversos , Peptídeo 1 Semelhante ao Glucagon/uso terapêutico , Hiperglicemia/tratamento farmacológico , Incretinas/uso terapêutico , Adulto , Idoso , Área Sob a Curva , Glicemia/metabolismo , Estado Terminal , Estudos Cross-Over , Método Duplo-Cego , Feminino , Glucagon/sangue , Peptídeo 1 Semelhante ao Glucagon/administração & dosagem , Peptídeo 1 Semelhante ao Glucagon/sangue , Humanos , Hiperglicemia/etiologia , Hipoglicemia/prevenção & controle , Incretinas/administração & dosagem , Infusões Intravenosas , Insulina/sangue , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA